Trial Profile
Can radiological parameters predict the outcome in metastatic renal cell carcinoma (mRCC) patients treated with first-line sunitinib?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Oct 2015 New trial record